Skip to content

Study on the Influence of Immunonutritional Intervention on the Immune Status of Patients with Acute Leukemia

Study on the Influence of Immunonutritional Intervention on the Immune Status of Patients with Acute Leukemia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099367
Enrollment
Unknown
Registered
2025-03-21
Start date
2024-11-20
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukemia

Interventions

treatment group:Subjects demonstrating nutritional supplement intake >60% of the recommended daily amount per day for =4 consecutive days.
observation group:Subjects who demonstrated nutritional supplement intake <60% of the recommended daily amount for =3 consecutive days.recommended daily amount for =3 consecutive days.

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for acute myeloid leukemia (AML); 2. Age from18 to 60 years old; 3. Absence of hepatic, renal, and digestive system diseases, other tumor diagnoses, immunodeficiency, and infectious diseases; 4. No use of antibiotics or immunoecological modulators within 30 days prior to hospitalization; 5. Barthel Index score for activity ability >=60 points, with body mass index (BMI) ranging from 18.5 kg/m² to 28 kg/m²; 6. Central venous catheter administration of chemotherapeutic agents.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Pre-existing infection (bacterial, fungal, or viral) or fever prior to hospitalization; 3. Primary gastrointestinal diseases including but not limited to Crohn's disease, ulcerative colitis, celiac disease, and short bowel syndrome; 4. Any documented gastrointestinal disorders associated with strictures, malignancies, and regional ischemia; 5. Psychiatric conditions or disorders that may interfere with study procedures or outcomes; 6. Incomplete medical records.

Design outcomes

Primary

MeasureTime frame
CD4+T lymphocyte;CD8+T lymphocyte;MBI-LCBIs;

Secondary

MeasureTime frame
Diamine Oxidase;Bacterial endotoxin;Costs Related to Bloodstream Infection Treatment;White blood cell;Hemoglobin;Platelet";High-sensitivity C-reactive protein;Blood culture;Body temperature;

Countries

China

Contacts

Public ContactLuo Guixiu

The First Affiliated Hospital of Guangxi Medical University

940365274@qq.com+86 156 7615 5662

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026